Selective atrophy of the cervical enlargement in whole spinal cord MRI of amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis
Atrophy
Cervical enlargement
Cross-sectional area
Magnetic resonance imaging
Spinal cord
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
revised:
26
08
2022
accepted:
13
09
2022
pubmed:
23
9
2022
medline:
15
12
2022
entrez:
22
9
2022
Statut:
ppublish
Résumé
Amyotrophic lateral sclerosis (ALS) is a deadly neurodegenerative disorder affecting motor neurons in the spinal cord and brain. Studies have reported on atrophy within segments of the cervical cord, but we are not aware of previous investigations of the whole spinal cord. Herein we present our findings from a 3T MRI study involving 32 subjects (15 ALS participants and 17 healthy controls) characterizing cross-sectional area along the entire cord. We report atrophy of the cervical enlargement in ALS participants, but no evidence of atrophy of the thoracolumbar enlargement. These results suggest that MR-based analyses of the cervical cord may be sufficient for in vivo investigations of spinal cord atrophy in ALS, and that atrophy of the cervical enlargement (C4-C7) is a potential imaging marker for quantifying lower motor neuron degradation.
Identifiants
pubmed: 36137496
pii: S2213-1582(22)00264-9
doi: 10.1016/j.nicl.2022.103199
pmc: PMC9668597
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103199Subventions
Organisme : NINDS NIH HHS
ID : R01 NS094306
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB030006
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB027779
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB015896
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS095937
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest In the past two years, J.M.H. has consulted for Amathus Therapeutics, Rodin Therapeutics, Abata Therapeutics, FogPharma, Sanofi-Aventis, Longitude Capital, and the Alzheimer’s Drug Discovery Foundation. J.M.H. is a paid Editor-in-Chief for ACS Chemical Neuroscience. J.M.H. is a co-founder and equity holder in Eikonizo Therapeutics (a license holder to J.M.H. patents) and in Sensorium Therapeutics. J.M.H. is a scientific advisory board member and equity holder in Psy Therapeutics, Delix Therapeutics, and Fuzionaire Diagnostics. J.M.H. has received sponsored research grants from Atai Life Sciences and Expesicor and has received honoraria for speaking or advisory service at non-profit academic institutions. N.A. is currently employed by Sanofi Genzyme. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.